Delisting riskPopularity #3,172
Outlook Therapeutics (OTLK)
Develops and commercializes ophthalmic bevacizumab for wet age-related macular degeneration.
$0.6732
vs last close−0.02 (−3.30%)
Something off on this page? Send us feedback.
Next report
Dec 18, 26
in 86 days
EPS estimate
−$0.06
Revenue estimate
$2.7M
Fiscal quarter
Q1 FY27
EPSReportedEstimate
Feb '25May '25Aug '25Dec '25Feb '26May '26Aug '26Dec '26
Reported−$0.89−$0.40−$0.44−$0.22−$0.22−$0.16−$0.14Pending
Estimate−$0.85−$0.55−$0.42−$0.23−$0.17−$0.12−$0.08−$0.06
Surprise−4.7%+27.3%−4.8%+4.3%−29.4%−33.3%−75.0%—
RevenueReportedEstimate
Feb '25May '25Aug '25Dec '25Feb '26May '26Aug '26Dec '26
Reported——$1.5M−$91.8K−$1.2M$128.0K$9.0KPending
Estimate$702.6K$628.3K$1.5M$5.8M$3.1M$4.4M$966.7K$2.7M
Surprise——+0.3%−101.6%−138.4%−97.1%−99.1%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2027 | −$0.02 | — | — |
| Jun 2027 | −$0.05 | — | — |
| Mar 2027 | −$0.05 | — | — |
| Dec 2026 | −$0.06 | — | — |
| Sep 2026 | −$0.07 | — | — |
| Aug 2026 | −$0.08 | −$0.14 | −75.0% |
| May 2026 | −$0.12 | −$0.16 | −33.3% |
| Feb 2026 | −$0.17 | −$0.22 | −29.4% |
| Dec 2025 | −$0.23 | −$0.22 | +4.3% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Dec 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Dec 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Dec 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Dec 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Dec 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Dec 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Dec 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| Jun 2017 | |||
| Feb 2017 | |||
| Dec 2016 | |||
| Aug 2016 | |||
| Jun 2016 | |||
| May 2016 | |||
| Sep 2015 | |||
| Jun 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 2027 | −$0.02 | — | — | $18.6M | — | — | — |
| Jun 2027 | −$0.05 | — | — | $11.1M | — | — | — |
| Mar 2027 | −$0.05 | — | — | $9.1M | — | — | — |
| Dec 18, 2026 | −$0.06 | — | — | $2.7M | — | — | — |
| Sep 2026 | −$0.07 | — | — | $2.7M | — | — | — |
| Aug 14, 2026 | −$0.08 | −$0.14 | −75.0% | $966.7K | $9.0K | −99.1% | −14.9% |
| May 15, 2026 | −$0.12 | −$0.16 | −33.3% | $4.4M | $128.0K | −97.1% | −2.2% |
| Feb 17, 2026 | −$0.17 | −$0.22 | −29.4% | $3.1M | −$1.2M | −138.4% | −13.8% |
| Dec 19, 2025 | −$0.23 | −$0.22 | +4.3% | $5.8M | −$91.8K | −101.6% | −2.9% |
| Aug 14, 2025 | |||||||
| May 15, 2025 | |||||||
| Feb 14, 2025 | |||||||
| Dec 27, 2024 | |||||||
| Aug 14, 2024 | |||||||
| May 16, 2024 | |||||||
| Feb 14, 2024 | |||||||
| Dec 22, 2023 | |||||||
| Aug 14, 2023 | |||||||
| May 15, 2023 | |||||||
| Feb 14, 2023 | |||||||
| Dec 29, 2022 | |||||||
| Aug 10, 2022 | |||||||
| May 13, 2022 | |||||||
| Feb 14, 2022 | |||||||
| Dec 22, 2021 | |||||||
| Aug 13, 2021 | |||||||
| May 14, 2021 | |||||||
| Feb 16, 2021 | |||||||
| Dec 23, 2020 | |||||||
| Aug 14, 2020 | |||||||
| May 15, 2020 | |||||||
| Feb 14, 2020 | |||||||
| Dec 19, 2019 | |||||||
| Aug 14, 2019 | |||||||
| May 15, 2019 | |||||||
| Feb 14, 2019 | |||||||
| Dec 18, 2018 | |||||||
| Aug 14, 2018 | |||||||
| May 15, 2018 | |||||||
| Feb 14, 2018 | |||||||
| Dec 29, 2017 | |||||||
| Aug 14, 2017 | |||||||
| Jun 28, 2017 | |||||||
| Feb 14, 2017 | |||||||
| Dec 29, 2016 | |||||||
| Aug 15, 2016 | |||||||
| Jun 27, 2016 | |||||||
| May 18, 2016 | |||||||
| Sep 30, 2015 | |||||||
| Jun 30, 2015 |